Ligand Pharmaceuticals Incorporated (LGNYZ)

Ligand Pharmaceuticals Incorporated (LGNYZ) — VMCI valuation read

LGNYZ screens at VMCI 59/100, a 9-point gap above the Healthcare sector median (50). For a mid-cap Ligand Pharmaceuticals Incorporated share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.

LGNYZ has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: LGNYZ trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 2.4x is the rate-sensitivity line to watch, which sets the rate-cycle exposure for Ligand Pharmaceuticals Incorporated.

LGNYZ fell 1.0% over the trailing 7 days, with a -21.2% read on a 30-day basis.